Drug intelligence / Profile preview

Olzep

Development stage: Unknown
Lead developer: Novanta
Modality: Small Molecules
Administration: Oral

Overview

Olzep is a brand of omeprazole, a proton pump inhibitor (PPI) developed and marketed by Arges Life Science Limited. It is a small molecule drug that irreversibly inhibits the H+/K+ ATPase enzyme system (the gastric proton pump) in the parietal cells of the stomach. By blocking the final step of acid production, it effectively reduces gastric acidity. Olzep is indicated for the treatment of acid-related gastrointestinal disorders, including gastroesophageal reflux disease (GERD), gastric and duodenal ulcers, erosive esophagitis, and hypersecretory conditions like Zollinger-Ellison syndrome. It is also used for the prevention and treatment of NSAID-associated gastric ulcers.

Brand names: Olzep
Other names: omeprazole

Targets

CYP3A4 (Cytochrome P450 3A4)ATP4A (Potassium–transporting ATPase alpha chain 1)CYP2C19 (Cytochrome P450 2C19)

Beyond the preview

Go deeper on Olzep.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Olzep.

Explore the full profile